Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jun;19(116):127-33.
doi: 10.1183/09059180.00003510.

Mucoactive drugs

R Balsamo  1 , L Lanata, C G Egan
Affiliations
Review

Mucoactive drugs

R Balsamo et al. Eur Respir Rev. 2010 Jun.

Abstract

Mucus hypersecretion is a clinical feature of severe respiratory diseases such as asthma, cystic fibrosis and chronic obstructive pulmonary disease. Airway mucosal infection and/or inflammation associated with these diseases often gives rise to inflammatory products, including neutrophil-derived DNA and filamentous actin, in addition to bacteria, apoptotic cells and cellular debris, that may collectively increase mucus production and viscosity. Mucoactive agents have been the medication of choice for the treatment of respiratory diseases in which mucus hypersecretion is a clinical complication. The main purpose of mucoactive drugs is to increase the ability to expectorate sputum and/or decrease mucus hypersecretion. Many mucoactive drugs are currently available and can be classified according to their putative mechanism of action. Mucoactive medications include expectorants, mucoregulators, mucolytics and mucokinetics. By developing our understanding of the specific effects of mucoactive agents, we may result in improved therapeutic use of these drugs. The present review provides a summary of the most clinically relevant mucoactive drugs in addition to their potential mechanism of action.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Chemical structures of selected expectorant, mucoregulatory, mucolytic and mucokinetic drugs.
See this image and copyright information in PMC

References

    1. Wanner A, Salathe M, O'Riordan TG. Mucociliary clearance in the airways. Am J Respir Crit Care Med 1996; 154: 1868–1902. - PubMed
    1. Rubin BK. The pharmacologic approach to airway clearance: mucoactive agents. Respir Care 2002; 47: 818–822. - PubMed
    1. King M, Rubin BK. Pharmacological approaches to discovery and development of new mucolytic agents. Adv Drug Deliv Rev 2002; 54: 1475–1490. - PubMed
    1. Rogers DF, Barnes PJ. Treatment of airway mucus hypersecretion. Ann Med 2006; 38: 116–125. - PubMed
    1. Rubin BK, van der Schans CP, eds. Therapy for Mucus Clearance Disorders. C. Lenfant, executive editor. Biology of the Lung Series. New York, Marcel Dekker, 2004.

MeSH terms